145 related articles for article (PubMed ID: 37007162)
1. Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review.
Liu Z; Yu M; Zhao F; Zhu C
Front Oncol; 2023; 13():976415. PubMed ID: 37007162
[TBL] [Abstract][Full Text] [Related]
2. Mixed squamous cell carcinoma and follicular carcinoma of the thyroid gland.
Mercante G; Marchesi A; Covello R; Dainese L; Spriano G
Auris Nasus Larynx; 2012 Jun; 39(3):310-3. PubMed ID: 21855238
[TBL] [Abstract][Full Text] [Related]
3. A Primary Squamous Cell Carcinoma of the Thyroid Presenting as the Anaplastic Thyroid Carcinoma: A Case Report.
Zheng RZ; Huang GH; Xu YJ
Front Surg; 2020; 7():590956. PubMed ID: 33195392
[No Abstract] [Full Text] [Related]
4. Analysis of primary and secondary squamous cell carcinoma of the thyroid gland: a retrospective study.
Liu G; Xu X; Chen G; Liu Z
Gland Surg; 2021 Feb; 10(2):559-566. PubMed ID: 33708539
[TBL] [Abstract][Full Text] [Related]
5. Primary squamous cell carcinoma of the thyroid: report of ten cases.
Booya F; Sebo TJ; Kasperbauer JL; Fatourechi V
Thyroid; 2006 Jan; 16(1):89-93. PubMed ID: 16487020
[TBL] [Abstract][Full Text] [Related]
6. Primary Squamous Cell Carcinoma of the Thyroid.
Raggio B; Barr J; Ghandour Z; Friedlander P
Ochsner J; 2019; 19(3):290-292. PubMed ID: 31528145
[No Abstract] [Full Text] [Related]
7. Primary Squamous Cell Carcinoma of the Thyroid: A Case Report and Literature Review About a Rare Entity.
Soror NN; Shah P; Hemrock L; Bennett R
Cureus; 2021 May; 13(5):e14963. PubMed ID: 34123660
[TBL] [Abstract][Full Text] [Related]
8. Paraneoplastic Manifestation of Primary Squamous Cell Cancer of the Thyroid Gland.
Sharma P S A; J R; B V MM; Kannan S
Cureus; 2023 May; 15(5):e39415. PubMed ID: 37362540
[TBL] [Abstract][Full Text] [Related]
9. Primary squamous cell carcinoma of thyroid gland: 11 case reports and a population-based study.
Yan W; Chen H; Li J; Zhou R; Su J
World J Surg Oncol; 2022 Nov; 20(1):352. PubMed ID: 36329478
[TBL] [Abstract][Full Text] [Related]
10. Total thyroidectomy associated to chemotherapy in primary squamous cell carcinoma of the thyroid.
De Cesare A; Di Cristofano C; Di Filippo AR; Salesi N; Spaziani M; Picchio M; Spaziani E
Clin Ter; 2019; 170(4):e231-e234. PubMed ID: 31304506
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of weekly paclitaxel therapy in unresectable primary squamous cell carcinoma of the thyroid.
Iwaki S; Kawakita D; Sawabe M; Matoba T; Takano G; Oguri K; Murashima A; Minohara K; Tanaka N; Tsuge H; Imaizumi S; Matsumura A; Masaki A; Murase T; Ogawa M; Iwasaki S
Auris Nasus Larynx; 2022 Dec; 49(6):1083-1087. PubMed ID: 34226099
[TBL] [Abstract][Full Text] [Related]
12. Treatment optimization and prognostic considerations for primary squamous cell carcinoma of the thyroid.
Wang W; Ouyang Q; Meng C; Jing L; Li X
Gland Surg; 2019 Dec; 8(6):683-690. PubMed ID: 32042676
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib plus Sintilimab achieved in an antitumor effect of complete remission in a patient with advanced hepatocellular carcinoma: a case report.
Sun C; Ma X; Jiang L; Zhu X
Anticancer Drugs; 2024 Apr; 35(4):358-361. PubMed ID: 38385998
[TBL] [Abstract][Full Text] [Related]
14. Primary squamous cell carcinoma of the thyroid: a case report.
Xin S; Li W; Yuan N; Shen C; Zhang D; Chai S
J Int Med Res; 2021 Apr; 49(4):3000605211004702. PubMed ID: 33827322
[TBL] [Abstract][Full Text] [Related]
15. Primary squamous cell carcinoma of the thyroid: an unusual presentation.
Batchelor NK
J Bronchology Interv Pulmonol; 2011 Apr; 18(2):168-70. PubMed ID: 23169089
[TBL] [Abstract][Full Text] [Related]
16. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
Chu T; Zhong R; Zhong H; Zhang B; Zhang W; Shi C; Qian J; Zhang Y; Chang Q; Zhang X; Dong Y; Teng J; Gao Z; Qiang H; Nie W; Zhao Y; Han Y; Chen Y; Han B
J Thorac Oncol; 2021 Apr; 16(4):643-652. PubMed ID: 33524601
[TBL] [Abstract][Full Text] [Related]
17. [Intervention of Vascular Dysplasia Caused by Different Mechanisms - Anlotinib for Right Lung Squamous Cell Carcinoma Combined with Thromboangiitis Obliterans: A Case Report and Literature Review].
Hao H; Zhang M; Zhang G; Zhu H; Bao W
Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):60-64. PubMed ID: 31948540
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation.
Cao JZ; Wu W; Pan JF; Wang HW; Jiang JH; Ma Q
Front Oncol; 2021; 11():643413. PubMed ID: 34109111
[TBL] [Abstract][Full Text] [Related]
19. Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature.
Yan J; Ma N; Qiao WL; Liu KQ; Liu DW; Wang Y; Qiao TT; Hao XQ; Zheng MD
Ann Transl Med; 2022 Dec; 10(24):1411. PubMed ID: 36660611
[TBL] [Abstract][Full Text] [Related]
20. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
